Related Experiment Video
Updated: Feb 8, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Advances and perspectives in CEA-targeted therapies: From classic biomarker toward actionable therapeutic target
Liangjie Sun1, Guo Zhao1, Jiawei Zhou1
1Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital of Chinese Academy of Medical Sciences Langfang Campus, Langfang 065001, China.
Abstract:
Carcinoembryonic antigen (CEA) stands as a classic and widely applied tumor biomarker mainly for epithelial malignancies. Its restricted tumor expression pattern and role in cellular adhesion render it a promising therapeutic target. However, the translation of CEA into effective therapies has long been hindered by multiple challenges. As the first comprehensive review of CEA-targeted therapies, we leveraged peer-reviewed literature and officially disclosed global pharmaceutical data to delineate the landscape and evaluate the prospects across all subfields of CEA-targeted drug modalities, including antibody-drug conjugates, chimeric antigen receptor T cells, bispecific antibodies, vaccines, and radionuclide conjugates. We also dissected the underlying mechanisms of the challenges contributing to these setbacks. By proposing multifaceted and innovative strategies, this review facilitates CEA's transition from a diagnostic and predictive biomarker to a viable therapeutic target, ultimately supporting improved clinical outcomes for patients with CEA-expressing cancers.
Insights
Carcinoembryonic antigen (CEA) is a tumor biomarker for epithelial cancers. This review explores CEA-targeted therapies, including antibody-drug conjugates and CAR T-cells, to overcome challenges and improve patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Carcinoembryonic antigen (CEA) is a well-established tumor biomarker for epithelial malignancies.
- CEA's restricted tumor expression and role in cellular adhesion make it a promising therapeutic target.
- Challenges have historically hindered the translation of CEA into effective therapies.
Purpose of the Study:
- To provide a comprehensive review of CEA-targeted therapies.
- To delineate the landscape and evaluate the prospects of various CEA-targeted drug modalities.
- To identify and propose strategies to overcome challenges in CEA-targeted therapy development.
Main Methods:
- Leveraged peer-reviewed literature and global pharmaceutical data.
- Reviewed antibody-drug conjugates, chimeric antigen receptor T cells, bispecific antibodies, vaccines, and radionuclide conjugates.
- Dissected underlying mechanisms of challenges in CEA-targeted therapies.
Main Results:
- Identified diverse CEA-targeted drug modalities with therapeutic potential.
- Highlighted significant challenges impeding the clinical translation of these therapies.
- Proposed innovative strategies to address identified obstacles.
Conclusions:
- CEA holds significant promise as a therapeutic target beyond its diagnostic role.
- Overcoming specific challenges is crucial for advancing CEA-targeted therapies.
- This review aims to facilitate CEA's transition to a viable therapeutic target for improved patient outcomes in CEA-expressing cancers.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
05:09Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Classical Conditioning
Ivan Pavlov observed that dogs...
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Principles of Classical Conditioning
During the...